^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    STRN-ALK fusion

    i
    Other names: STRN, Striatin, Protein Phosphatase 2 Regulatory Subunit B'''Alpha, Striatin Calmodulin Binding Protein, Striatin Calmodulin-Binding Protein, PPP2R6A, SG2NA, STRN1, NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor
    Entrez ID:
    238; 6801
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    1year
    STRN-ALK Fusion in Advanced Salivary Gland Carcinoma With Response to Anaplastic Lymphoma Kinase Inhibition: Case Report and Literature Review. (PubMed, WMJ)
    Our patient experienced clinical benefit from first and second generation ALK inhibition in a chemotherapy refractory tumor. Tumor mutation profiling can identify mutations that may render tumors sensitive to targeted therapy with tyrosine kinase inhibitors.
    Review • Journal • Metastases
    |
    ALK (Anaplastic lymphoma kinase) • STRN (Striatin)
    |
    ALK fusion • ALK translocation • STRN-ALK fusion
    over1year
    Clinicopathologic Features and Cytologic Correlation of ALK-Rearranged Papillary Thyroid Carcinoma: A Series of Eight Cases. (PubMed, Endocr Pathol)
    The NGS testing revealed EML4::ALK fusion in three, STRN::ALK fusion in two, and ITSN2::ALK fusion in one. In conclusion, although ALK-rearranged PTCs have been associated with neutral gene expression profile from a BRAF-RAS scoring perspective, the "RAS-like" nuclear features were more commonly identified in this series, resulting in frequent indeterminate diagnosis of preoperative FNA.
    Journal
    |
    BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • EML4 (EMAP Like 4) • STRN (Striatin) • RAS (Rat Sarcoma Virus)
    |
    ALK rearrangement • ALK fusion • STRN-ALK fusion
    |
    VENTANA ALK (D5F3) CDx Assay
    over1year
    Reticular Myxoid Odontogenic Neoplasm with Novel STRN::ALK Fusion: Report of 2 Cases in 3-Year-Old Males. (PubMed, Head Neck Pathol)
    Both patients were treated with surgical resection and reconstruction. The prognosis of patients with this entity is currently uncertain but shall become more apparent over time as more cases are identified and followed.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • STRN (Striatin)
    |
    ALK rearrangement • ALK fusion • STRN-ALK fusion
    almost2years
    Ciliated Muconodular Papillary Tumors of the Lung Harboring STRN::ALK Fusion: Case Report and Review of the Literature. (PubMed, Int J Surg Pathol)
    Consequently, we conducted a review of relevant literature, summarizing the clinicopathological and molecular characteristics of CMPT to facilitate further research. Our insights enhance the understanding of this uncommon tumor and contribute to the expansion of its molecular alteration spectrum.
    Review • Journal
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • STRN (Striatin)
    |
    ALK rearrangement • ALK fusion • STRN-ALK fusion • EGFR rearrangement
    2years
    Plasma-Based Genotyping For Monitoring Patients With Thyroid Cancer (ATA 2023)
    Although the methodology is still evolving, our findings suggest that this non‐invasive approach can be incorporated into the routine management of patients with malignant thyroid neoplasm as it may help the early detection of therapeutically targetable mutations. We emphasize that liquid biopsy test can be repeated through the follow‐up to complement existing tests with low cost and convenience for the patient. We also anticipate that that this blood test may help early detection of thyroid tumors.
    Clinical
    |
    BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TERT (Telomerase Reverse Transcriptase) • STRN (Striatin) • RAS (Rat Sarcoma Virus) • AGK (Acylglycerol Kinase) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • PAX8 (Paired box 8)
    |
    BRAF V600E • BRAF V600 • BRAF fusion • AGK-BRAF fusion • STRN-ALK fusion
    over2years
    Liquid Biopsy-based Umbrella Trial for Advanced NSCLC: Results of Phase 2 Plasma ALK-positive Cohort (A-Liquid) (IASLC-WCLC 2023)
    Although precision medicine based on liquid NGS remains challenging due to the low PPA for fusion genes, alectinib is active in highly selected NSCLC populations with ALK rearrangement detected by both tissue-based assays and liquid NGS. Additional analysis on resistance mechanisms using paired blood samples will be presented.
    P2 data • Liquid biopsy • Metastases • Biopsy
    |
    ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • EML4 (EMAP Like 4) • STRN (Striatin)
    |
    ALK positive • ALK rearrangement • ALK fusion • ROS1 fusion • ROS1 positive • STRN-ALK fusion • ALK-ROS1 fusion
    |
    Guardant360® CDx
    |
    Alecensa (alectinib)
    over2years
    Molecular genetics of diffuse sclerosing papillary thyroid cancer. (PubMed, J Clin Endocrinol Metab)
    In DSPTC, fusion genes are common, BRAFV600E is rare, and other usual point mutations are absent. Pathogenic and likely pathogenic variants in POLE, NF1, CDKN2A, BRCA2, TP53, SETD2, ATM, FLT3 and ROS1 occur in about two-thirds of DTPTC.
    Journal • BRCA Biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • FLT3 (Fms-related tyrosine kinase 3) • NRAS (Neuroblastoma RAS viral oncogene homolog) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • HRAS (Harvey rat sarcoma viral oncogene homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • NF1 (Neurofibromin 1) • CCDC6 (Coiled-Coil Domain Containing 6) • STRN (Striatin) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase) • NCOA4 (Nuclear Receptor Coactivator 4)
    |
    TP53 mutation • BRAF V600E • PIK3CA mutation • PTEN mutation • ALK fusion • ALK mutation • STRN-ALK fusion
    3years
    Therapeutic Advances of Rare ALK Fusions in Non-Small Cell Lung Cancer. (PubMed, Curr Oncol)
    Recent clinical studies in the ALK-positive NSCLC population have demonstrated differences in progression-free survival (PFS) among patients based on different ALK fusion subtypes. This article will introduce the biological characteristics of ALK fusion kinase and common detection methods of ALK fusion and focus on summarizing the differential responses of several rare ALK fusions to ALK-TKIs, and propose corresponding treatment strategies, so as to better guide the application of ALK-TKIs in rare ALK fusion population.
    Review • Journal • IO biomarker
    |
    ALK (Anaplastic lymphoma kinase) • EML4 (EMAP Like 4) • STRN (Striatin) • HIP1 (Huntingtin Interacting Protein 1)
    |
    ALK positive • ALK fusion • ALK mutation • STRN-ALK fusion
    3years
    DIFFUSE SCLEROSING PAPILLARY THYROID CANCER: PATHOLOGICAL FEATURES, MOLECULAR GENETICS AND OUTCOME (ATA 2022)
    DSVPTC is an aggressive type of PTC affecting mostly young patients and is characterized by frequent lymph node and distant metastases. Fusion genes especially RET‐PTC1 are the most common genetic alterations. BRAF V600E and other usual somatic point mutations are rare to absent.
    Late-breaking abstract • BRCA Biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • FLT3 (Fms-related tyrosine kinase 3) • NRAS (Neuroblastoma RAS viral oncogene homolog) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • HRAS (Harvey rat sarcoma viral oncogene homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • NF1 (Neurofibromin 1) • TERT (Telomerase Reverse Transcriptase) • STRN (Striatin) • FGFR4 (Fibroblast growth factor receptor 4) • TSC2 (TSC complex subunit 2) • RAS (Rat Sarcoma Virus) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase) • NCOA4 (Nuclear Receptor Coactivator 4)
    |
    TP53 mutation • BRAF V600E • KRAS mutation • NRAS mutation • PIK3CA mutation • BRAF V600 • PTEN mutation • NF1 mutation • ALK fusion • HRAS mutation • FGFR4 mutation • TSC2 mutation • STRN-ALK fusion
    |
    Oncomine™ Comprehensive Assay v3M
    3years
    THE IN VITRO EFFECT OF ALK INHIBITORS IN STRN‐ALK ANAPLASTIC THYROID CANCER (ATA 2022)
    This study permitted to evaluate in vitro the antineoplastic effect of crizotinib in human pATC (with STRN‐ALK), opening the way to future clinical evaluations in these patients.
    Preclinical
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • HRAS (Harvey rat sarcoma viral oncogene homolog) • STRN (Striatin) • NCOA4 (Nuclear Receptor Coactivator 4) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • PAX8 (Paired box 8)
    |
    KRAS mutation • BRAF mutation • NRAS mutation • ALK positive • ALK rearrangement • ALK fusion • ALK mutation • HRAS mutation • STRN-ALK fusion
    |
    Xalkori (crizotinib)
    almost4years
    Acquired concurrent EGFR T790M and driver gene resistance from EGFR-TKIs hampered osimertinib efficacy in advanced lung adenocarcinoma (ELCC 2022)
    One patient had acquired EGFR T790M, STRN-ALK fusion, and EGFR amplification after gefitinib progression and was shortly resistant to osimertinib with MET amplification. The other patient developed to acquired EGFR T790M and MET amplification post-dacomitinib and acquired CCDC6-RET fusion after 4-month osimertinib treatment...The T790M accompanying diver gene resistance will be a new subtype after EGFR-TKIs progression and needs effective treatment options. Legal entity responsible for the study The authors.
    Clinical
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • CCDC6 (Coiled-Coil Domain Containing 6) • STRN (Striatin)
    |
    EGFR mutation • HER-2 amplification • MET amplification • EGFR T790M • RET fusion • EGFR amplification • ALK fusion • CCDC6-RET fusion • KRAS G12 • KRAS amplification • STRN-ALK fusion • ALK amplification • EGFR T790M + HER-2 amplification • EGFR T790M + MET amplification
    |
    Tagrisso (osimertinib) • gefitinib • Vizimpro (dacomitinib)
    almost4years
    Clinical and molecular characterization of thyroid cancer when seen as a second malignant neoplasm. (PubMed, Ther Adv Endocrinol Metab)
    Monitoring of cancer survivors for thyroid disorders allowed diagnosis of second thyroid cancers at early stages. Second thyroid cancers harbor genomic alterations that are typical for sporadic as well as for radio-induced thyroid cancers.
    Journal
    |
    BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • STRN (Striatin)
    |
    BRAF mutation • RET fusion • ALK fusion • RET mutation • STRN-ALK fusion
    |
    Oncomine Focus Assay